Economic impact of inappropriate histamine2-receptor antagonist use

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 1085-1091

  Wadibia, E Chuma ^a   Lucas, B Daniel ^b   Hilleman, Daniel E ^c   Mooss, Aryan N ^c  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gastrointestinal disorders; Pharmacoeconomics; Stress ulcer prophylaxis

Indexed keywords

CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY CARE UNIT; DRUG COST; DRUG INDICATION; DRUG UTILIZATION; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; STRESS ULCER; ZOLLINGER ELLISON SYNDROME;

EID: 0030723532     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80061-6     Document Type: Article

References (20)

1. Feldman M, Burton ME. Histamine 2 receptor antagonists. NEJM. 1990;323: 1672-1680.
2. Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: Suggested disease management guidelines. Arch Intern Med. 1996;155:922-928.
3. Soll AH, for the Practice Parameters Committee of the American College of Gastroenterology. Consensus statement: Medical treatment of peptic ulcer disease: Practice guidelines. JAMA. 1996;276: 983-988.
4. Davis TG, Pickett DL, Schlosser JH. Evaluation of a world wide spontaneous reporting system with cimetidine. JAMA. 1980;243:1912-1914.
5. Colin Jones DG, Langman MJS, Lawson DH, Vessey MP. Post marketing surveillance of the safety of cimetidine: Twelve-month morbidity report. Q J Med. 1985;54: 253-268.
6. 2-antagonists. Med Toxicol Adverse Drug Exp. 1986;1:192-216.
7. Humphries TJ, Myerson RM, Gifford LM, et al. A unique post market outpatient surveillance program of cimetidine: Report on phase II and final summary. Am J Gastroenterol. 1984;79:593-596.
8. Eandi M, De Carli GF, Buraglio M, Recchia G. Ranitidine: Seven years of drug surveillance. Clin Trials J. 1988;25:152-157.
9. Colin Jones DG, Langman MJS, Lawson DH, Vessey P. Postmarketing surveillance of the safety of cimetidine: Mortality during second, third and fourth years of follow up. BMJ. 1985;291:1084-1088.
10. 2-receptor antagonists: Current status of famotidine. J Int Med Res. 1989;17(Suppl 1):48A-53A.
11. McGuigan JE. Safety of cimetidine: An overview. Drug Ther. 1983;(Suppl):179-184.
12. Hunt RH. Safety of ranitidine: An overview. Drug Ther. 1983;(Suppl):185-189.
13. Saigenji K, Fukotomi H, Nakazawa S. Famotidine: Postmarketing clinical experience. Scand J Gastroenterol. 1987;22 (Suppl 134):34-40.
14. Lipsy RJ, Fennerty B, Fagan TC. Clinical review of histamine 2 receptor antagonists. Arch Intern Med. 1990;150:745-751.
15. 2-antagonist therapy. Aliment Pharmacol Ther. 1991;5(Suppl 1):49-57.
16. Oh T, Franko TG. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine. Am J Hosp Pharm. 1990:47:1547-1551.
17. 2-antagonist therapy. Am J Hosp Pharm. 1989;46:1183-1184.
18. 2 receptor antagonists. Drug Intell Clin Pharm. 1987;21:335-339.
19. 2-antagonist therapy. Hosp Pharm. 1987;22:1205-1209.
20. Gerry R. Prescription drugs invade the over-the-counter market. Pharmaceutical News Capsule. 1992;9:8-9.